Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

Hidetsugu Saito, Kanji Tsuchimoto, Shingo Miyaguchi, Shinichiro Tada, Kentaro Sawaguchi, Kohichi Komatsu, Kohtaro Kaneko, Tetsu Watanabe, Toshio Morizane, Hiromasa Ishii

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

Original languageEnglish
Pages (from-to)161-167
Number of pages7
JournalKeio Journal of Medicine
Volume45
Issue number3
Publication statusPublished - 1996 Sep

Fingerprint

Chronic Hepatitis C
Interferons
Multicenter Studies
Hepacivirus
RNA
Therapeutics
Alanine Transaminase
Reverse Transcription
Polymerase Chain Reaction
Serum

Keywords

  • chronic hepatitis C
  • dose study
  • interferon
  • prediction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Saito, H., Tsuchimoto, K., Miyaguchi, S., Tada, S., Sawaguchi, K., Komatsu, K., ... Ishii, H. (1996). Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C. Keio Journal of Medicine, 45(3), 161-167.

Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C. / Saito, Hidetsugu; Tsuchimoto, Kanji; Miyaguchi, Shingo; Tada, Shinichiro; Sawaguchi, Kentaro; Komatsu, Kohichi; Kaneko, Kohtaro; Watanabe, Tetsu; Morizane, Toshio; Ishii, Hiromasa.

In: Keio Journal of Medicine, Vol. 45, No. 3, 09.1996, p. 161-167.

Research output: Contribution to journalArticle

Saito, H, Tsuchimoto, K, Miyaguchi, S, Tada, S, Sawaguchi, K, Komatsu, K, Kaneko, K, Watanabe, T, Morizane, T & Ishii, H 1996, 'Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C', Keio Journal of Medicine, vol. 45, no. 3, pp. 161-167.
Saito H, Tsuchimoto K, Miyaguchi S, Tada S, Sawaguchi K, Komatsu K et al. Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C. Keio Journal of Medicine. 1996 Sep;45(3):161-167.
Saito, Hidetsugu ; Tsuchimoto, Kanji ; Miyaguchi, Shingo ; Tada, Shinichiro ; Sawaguchi, Kentaro ; Komatsu, Kohichi ; Kaneko, Kohtaro ; Watanabe, Tetsu ; Morizane, Toshio ; Ishii, Hiromasa. / Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C. In: Keio Journal of Medicine. 1996 ; Vol. 45, No. 3. pp. 161-167.
@article{0b207bc562424e9f80614b5f20599177,
title = "Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C",
abstract = "The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1{\%} and 51.6{\%} of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9{\%} and 35.7{\%} of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.",
keywords = "chronic hepatitis C, dose study, interferon, prediction",
author = "Hidetsugu Saito and Kanji Tsuchimoto and Shingo Miyaguchi and Shinichiro Tada and Kentaro Sawaguchi and Kohichi Komatsu and Kohtaro Kaneko and Tetsu Watanabe and Toshio Morizane and Hiromasa Ishii",
year = "1996",
month = "9",
language = "English",
volume = "45",
pages = "161--167",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "3",

}

TY - JOUR

T1 - Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

AU - Saito, Hidetsugu

AU - Tsuchimoto, Kanji

AU - Miyaguchi, Shingo

AU - Tada, Shinichiro

AU - Sawaguchi, Kentaro

AU - Komatsu, Kohichi

AU - Kaneko, Kohtaro

AU - Watanabe, Tetsu

AU - Morizane, Toshio

AU - Ishii, Hiromasa

PY - 1996/9

Y1 - 1996/9

N2 - The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

AB - The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

KW - chronic hepatitis C

KW - dose study

KW - interferon

KW - prediction

UR - http://www.scopus.com/inward/record.url?scp=0344532668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344532668&partnerID=8YFLogxK

M3 - Article

C2 - 8897759

AN - SCOPUS:0344532668

VL - 45

SP - 161

EP - 167

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 3

ER -